HANFREMA Trademark

Trademark Overview


On Tuesday, November 30, 2021, a trademark application was filed for HANFREMA with the United States Patent and Trademark Office. The USPTO has given the HANFREMA trademark a serial number of 97148205. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Thursday, February 23, 2023. This trademark is owned by CSL Behring GmbH. The HANFREMA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits co...
hanfrema

General Information


Serial Number97148205
Word MarkHANFREMA
Filing DateTuesday, November 30, 2021
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateThursday, February 23, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 3, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
Translation of Words in MarkThe wording "HANFREMA" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateThursday, February 23, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCSL Behring GmbH
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMarburg D-35041
DE

Party NameCSL Behring GmbH
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMarburg D-35041
DE

Trademark Events


Event DateEvent Description
Thursday, February 23, 2023ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Thursday, February 23, 2023ABANDONMENT - AFTER PUBLICATION
Wednesday, February 22, 2023TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, January 31, 2023EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, January 3, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 3, 2023PUBLISHED FOR OPPOSITION
Wednesday, December 14, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, December 1, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, November 5, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, November 5, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, November 4, 2022ASSIGNED TO LIE
Thursday, September 22, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 8, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 8, 2022NON-FINAL ACTION E-MAILED
Thursday, September 8, 2022NON-FINAL ACTION WRITTEN
Thursday, September 8, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 8, 2022NON-FINAL ACTION E-MAILED
Thursday, September 8, 2022NON-FINAL ACTION WRITTEN
Thursday, September 8, 2022ASSIGNED TO EXAMINER
Friday, December 3, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, December 3, 2021NEW APPLICATION ENTERED